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BACKGROUND: Given the uncertainty surrounding the optimal management for early stage bladder cancer, physi-
cians vary in how they approach the disease. The authors of this report linked cancer registry data with medical
claims to identify the sources of variation and opportunities for improving the value of cancer care. METHODS: By
using data from the Surveillance, Epidemiology, and End Results-Medicare database (1992-2005), patients with early
stage bladder cancer were abstracted (n ¼ 18,276). The primary outcome was the intensity of initial treatment that
patients received, as measured by all Medicare payments for bladder cancer incurred in the 2 years after diagnosis.
Multilevel models were fitted to partition the variation in treatment intensity attributable to patient versus provider
factors, and the potential savings to Medicare from reducing the physician contribution were estimated. RESULTS:
Provider factors accounted for 9.2% of the variation in treatment intensity. Increasing provider treatment intensity did
not correlate with improved cancer-specific survival (P ¼ .07), but it was associated with the subsequent receipt of
major interventions, including radical cystectomy (P < .001). If provider-level variation was reduced and clinical prac-
tice was aligned with that of physicians who performed in the 25th percentile of treatment intensity, then total pay-
ments made for the average patient could be lowered by 18.6%, saving Medicare $18.7 million annually.
CONCLUSIONS: The current results indicated that a substantial amount of the variation in initial treatment intensity
for early stage bladder cancer is driven by the physician. Furthermore, a more intensive practice style was not associ-
ated with improved cancer-specific survival or the avoidance of major interventions. Therefore, interventions aimed
at reducing between-provider differences may improve the value of cancer care. Cancer 2010;116;3587–94. VC 2010
American Cancer Society.
KEYWORDS: bladder neoplasms, cost of illness, physician practice patterns, Surveillance, Epidemiology, and End
Results Program.
Because mortality from muscle-invasive bladder cancer is common, the goal of initial management for early stage
(ie, superficial) disease is to prevent progression. Although this goal is clear, how best to achieve it is not. Contemporary
practice guidelines for early stage bladder cancer reflect a view held by many authorities favoring intensive surveillance and
treatment.1,2 Implicit in such an approach is that more care prevents progression (and prolongs survival) or, at the very
least, allows for the detection of recurrences early enough so that subsequent interventions are more successful and
palatable.
However, the evidence base for these guidelines is limited and often relies on medical theory and expert opinion. For
example, surveillance recommendations call for frequent and regular endoscopies. Yet data supporting such recommenda-
tions were derived from a single trial of less than 100 patients.3 Moreover, the basis for the intensive treatment regimens
promoted by current guidelines is extrapolated largely from intermediate outcomes. Although the use of intravesical ther-
apy can lengthen the interval between recurrences,4,5 its benefits for imperative outcomes (eg, progression) are less certain.
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Indeed, patients with early stage disease fare no better
when treated by physicians who provide more intensive
initial treatment.6
With the uncertainty on how best to manage early
stage bladder cancer, physicians vary widely in their
approach.7-10 Given the spectrum of disease severity
among this population, a ‘‘1-size-fits-all’’ approach is
impractical. Insofar as patient factors explain the differen-
ces in physician practice, this variation may be appropri-
ate. However, to the extent that the physician is a
significant driver of this variation, efforts to decrease prac-
tice differences, especially those that add little benefit, are
warranted. For this reason, we performed a study using
Surveillance, Epidemiology, and End Results (SEER)-
Medicare data to understand the sources of variation in
the treatment of early stage disease as well as opportunities
for improving the value of cancer care.
MATERIALS AND METHODS
Database and Patients
For this study, we used SEER-Medicare data for the years
1992 through 2002. Patients were followed using Medi-
care claims through December 31, 2005. The cancer-spe-
cific information collected by the SEER Program is
generally representative of the entire United States popu-
lation.11 Data regarding tumor incidence, treatment, and
mortality can be linked successfully with hospital, physi-
cian, and other medical service claims for greater than
90% of the Medicare beneficiaries who are tracked by
SEER.12 By using appropriate SEER site-specific codes
(67.0-67.9), we abstracted data on all Medicare beneficia-
ries ages 65 to 99 years in the SEER Patient Entitlement
and Diagnosis Summary file who had an incident case of
early stage (modified American Joint Commission on
Cancer13 stages 0 and 1) bladder cancer. The study was
limited further to fee-for-service patients who were eligi-
ble for both Part A and Part B of Medicare throughout
the study interval.
To identify the physician primarily responsible for
providing a patient’s bladder cancer care, we examined all
bladder cancer-related procedures (as described in detail
by Schrag and colleagues9) performed in the first 2 years
after diagnosis. By using a physician-specific identifier, we
assigned each patient to the provider who performed the
majority of these procedures. To ensure the reliability sur-
rounding each provider’s practice style, we limited our
study to those providers who treated at least 10 patients
during the study period. Our final cohort consisted of
18,276 patients with early stage bladder cancer who were
cared for by 907 providers.
Outcomes
With the patient serving as the unit of analysis, our pri-
mary outcome was the initial treatment intensity received,
as measured by all Medicare payments for bladder cancer
incurred during the first 2 years after diagnosis.14 First, we
identified all claims associated with a primary diagnosis
code for bladder cancer (International Classification of
Diseases, Ninth Revision [ICD-9], Clinical Modification
codes: 188.x [bladder cancer], 233.7 [carcinoma in situ of
the bladder], and V105.4 [personal history of bladder can-
cer]) from the inpatient, outpatient, and carrier files.
Next, we tallied the total payments for these claims, stand-
ardized these to 2005 US dollars, and price-adjusted them
to account for regional differences inMedicare reimburse-
ment.15 Because these data were positively skewed, we
applied a logarithmic transformation to normalize them.
For our secondary outcomes, we measured bladder
cancer-specific survival using the cause-of-death field
available in SEER. We assessed survival from January 1,
1992 through December 31, 2005. We also determined a
patient’s subsequent need for a major intervention (as evi-
denced by the receipt of radical cystectomy, systemic
chemotherapy, or radiation treatment). We identified
these procedures using appropriate ICD-9 procedure
codes and Healthcare Common Procedure Coding Sys-
tem (HCPCS) codes.
Characterizing Patients and Providers
Subsequently, we constructed a variety of patient-level
variables hypothesized to influence the intensity of care.
In particular, we used the SEER records and Medicare
claims to categorize patients by their age at diagnosis, sex,
race/ethnicity (white, black, other), socioeconomic status,
level of comorbidity, geographic region of residence (the
hospital referral region [HRR] boundaries defined by the
Dartmouth Atlas of Health Care16), tumor grade (low, me-
dium, high, unknown), and tumor stage (Ta, tumor in
situ [Tis], T1, Ta/T1 not otherwise specified). We
assessed socioeconomic status at the patient zip code level
using a composite measure.17 With an adaptation of the
Charlson index,18 we examined patients’ healthcare
encounters in the 12-month period preceding their cancer
diagnosis to determine their comorbid illnesses.19
Through patients’ Medicare claims, we also distinguished
between those who experienced a bladder cancer recur-
rence and those who did not. Specifically, we defined a
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patient as having recurrent disease if he underwent a trans-
urethral bladder resection of bladder tumor (HCPCS
codes 52234, 52235, and 52240) more than 60 days after
his date of diagnosis.
To characterize the physicians who provided bladder
cancer care, we linked their Medicare claims with the
American Medical Association Masterfile through the
providers’ Unique Physician Identifier Numbers.20 On
the basis of the Masterfile data, we built variables that
indicated each physician’s sex, type of degree (Medical
Doctor vs Doctor of Osteopathy), location of training
(US graduate vs non-US graduate), and decade of medical
school graduation. In addition, we identified those pro-
viders who were urologists using the Masterfile’s primary
specialty designation. We also determined the number of
patients with early stage disease that each provider treated
during the study period.
Statistical Analysis
We used multilevel models to examine our continuous de-
pendent variable: treatment intensity. We fitted 2-level
linear mixed models with random intercepts. Our level-1
unit was the patient, and our level-2 unit was the provider.
Our initial model was a random intercept model with
only the provider identifier as a random effect and no ex-
planatory variables. This ‘‘empty’’ model allowed us to
understand the basic partitioning of the variation in treat-
ment intensity between the patient and the provider.
From the empty model, we determined the percentage of
the total variance that was caused by unmeasured
between-provider differences (ie, the provider intraclass
correlation21). We then proceeded to add in sets of inde-
pendent variables as fixed effects (diagnosis year, patient
characteristics, tumor features, recurrent disease status,
provider factors, and HRR) and measured the degree to
which each set changed the amount of between-provider
variation in treatment intensity.
Next, we fitted another series of multilevel models
from which the variance was partitioned further into con-
tributions from the measured provider and patient charac-
teristics. Each model included the provider identifier as a
random effect and only 1 of the following independent
variables: patient age, sex, race/ethnicity, socioeconomic
status, level of comorbidity, geographic region, tumor
grade and stage, whether the patient had a subsequent
bladder cancer recurrence, and diagnosis year. We calcu-
lated the percentage of the total variance explained by
each variable. This allowed us to understand the impor-
tance of each variable relative to the overall variation in
treatment intensity.
Then, we estimated providers’ average treatment in-
tensity from our multilevel models (controlling for patient
characteristics, tumor features, recurrent disease status, and
diagnosis year) using empirical Bayes methods. Empirical
Bayes estimates account for differences in the reliability of
individual measures of provider treatment intensity that
result from variations in the size of a physician’s patient
panel by adjusting each provider-specific measure toward
the overall mean as a factor of the physician’s panel size.22
Because our linear mixed models were based on the log of
total payments, it was necessary for us to retransform our
predicted values back to their original scale.23
After ranking providers by their treatment intensity
from lowest to highest, we sorted them into 20 equal
quantiles. We measured the degree of correlation between
a provider’s treatment intensity quantile and patient me-
dian cancer-specific survival as well as subsequent need for
major intervention, using the Kendall rank correlation
coefficient. Finally, we determined the potential annual
savings per patient from reducing physician variation in
treatment intensity using parameters from our previous
models and simulated datasets in which we changed all
providers’ practice habits to be similar to those of the
physicians residing in 1 of the treatment intensity quan-
tiles (beginning at the 5th percentile and ending with the
95th). We estimated possible implications for the Medi-
care program by reducing practice variation based on the
assumption of 45,000 incident cases of early stage bladder
cancer diagnosed annually.24
We carried out all analyses using the SAS statistical
package (version 9.1; SAS Institute, Cary, NC). All tests
were 2-tailed, and we set the probability of Type 1 error at
0.05. The Institutional Review Board of the University of
Michigan approved this study.
RESULTS
Over the study interval, mean expenditures per patient
were $4744. White men aged >74 years represented the
majority of patients in our study population, as displayed
in Table 1. Low-to-medium grade and stage Ta tumors
were the most common cancers at diagnosis, and 49.4%
of patients had recurrent disease. Figure 1 depicts the pro-
portion of variation in treatment intensity explained by
measurable patient demographics and tumor features.
Subsequent bladder cancer recurrence explained the high-
est percentage of the total variance (16%). Patient age,
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sex, race/ethnicity, socioeconomic status, level of comor-
bidity, and geographic region of residence contributed
minimally to the observed variation, accounting for <2%
of the total variance combined.
The majority of physicians in our cohort were US-
trained, male urologists who completed their medical
schooling before the 1980s (Table 1). On average, each
provider cared for 17 patients with early stage bladder
cancer during the study period, and the mean (standard
deviation) follow-up was 62.4 38.4 months. According
to our empty model, the estimated proportion of the
unexplained variance that was accounted for by unmeas-
ured provider factors was 9.2%. The size of the physician
effect on initial treatment intensity exceeded that attribut-
able to all measurable patient characteristics and tumor
stage and grade (Fig. 1). In our final model, we were able
to explain only 18.7% of the provider-level variation.
After sorting physicians into quantiles using their
estimated per patient expenditures (Fig. 2A), we observed
no significant correlation between increasing provider
treatment intensity and patient median cancer-specific
survival (P ¼ .07). However, despite no measurable
Figure 1. This chart illustrates the proportion of variation in
treatment intensity explained by patient-level factors. A se-
ries of 2-level models was fitted that included the provider as
a random effect and each of the following variables as a fixed
effect: patient age, sex, race/ethnicity, socioeconomic status,
comorbidity, tumor grade, tumor classification, recurrent dis-
ease status, and diagnosis year. A 2-level random effects
model with a random intercept (provider in our analysis)
and some predictor variables with fixed effects but no other
random effects can be written as follows: Yij ¼ c0 þ RchXhij þ
U0j þ Rij, in which the fixed part of the model is Yij ¼ c0 þ
RXhij and constitutes the linear predictor for Y with a variance
of r2F.
21 The percentage of total variance explained by each
was calculated. The explained proportion of the level-1
(patient) variance (var) is defined as the proportional reduc-
tion in mean squared prediction error, which can be written
as 1  (var[Yij  RchXhij]/var[Yij]). Intraclass correlation (or the
proportion of the variance attributable to the provider) is
equal to s20/(s
2
0 þ r2), in which s20 is the level-2 variance, and
r2 is the level-1 variance.































Carcinoma in situ 7
Ta/T1 not otherwise specified 11.1
Bladder cancer recurrence 49.4
Physicians (N¼907)








Primary specialty is urology 98.5
Bladder cancer volume
Low (£19 patients with early
stage bladder cancer)
35.5
Medium (20-34 patients) 32
High (‡35 patients) 32.5
Women 1.9
Original Article
3590 Cancer August 1, 2010
differences in the level of disease severity treated (P <
.001), there was a positive correlation, albeit small,
between increasing provider treatment intensity and a
patient’s subsequent receipt of radical cystectomy
(Fig. 2B) (tau ¼ 0.019; P < .001), as well as radiation
treatment (tau ¼ 0.018; P < .001) and systemic chemo-
therapy (tau¼ 0.030; P< .001). Table 2 displays the cost
savings achieved by eliminating the contribution of physi-
cian practice style to the variation in treatment intensity
for the typical patient with early stage bladder cancer. For
example, if all physicians’ care was similar to that of the
physicians in the 25th percentile of treatment intensity,
then total payments would be lowered by a minimum of
18.6% ($832), which would translate into an annual sav-
ings of $18,720,000 for Medicare (Fig. 3).
Figure 2. These charts illustrate the correlations between ini-
tial treatment intensity, (A) median cancer-specific survival,
and (B) the use of radical cystectomy. Providers were ranked
according to their treatment intensity from lowest to highest
and were sorted into 20 quantiles. With respect to tumor
classification (stacked bar chart), the level of disease severity
was similar across quantiles (P ¼ 1). Treatment intensity was
not correlated with median cancer-specific survival (P ¼ .12);
however, it was associated with undergoing radical cystec-
tomy (P < .001). NOS indicates not otherwise specified; Tis,
carcinoma in situ.
Table 2. The Effect of Reducing Physician-Attributable














5th 2833 36.7 1641
10th 3103 30.6 1371
15th 3309 26 1165
20th 3489 22 985
25th 3642 18.6 832
30th 3790 15.3 684
35th 3877 13.3 597
40th 3978 11.1 496
45th 4127 7.8 347
50th 4233 5.4 241
55th 4379 2.1 95
60th 4549 1.7 75
65th 4677 4.6 203
70th 4865 8.8 391
75th 5048 12.9 574
80th 5306 18.6 832
85th 5637 26 1163
90th 5985 33.8 1511
95th 6507 45.5 2033
aAverage expenditures per patient were predicted by running multilevel
models on simulated datasets in which all providers’ practice habits were
changed to be similar to those of the physicians from 1 of the treatment-in-
tensity quantiles (beginning at the 5th percentile and ending with the 95th
percentile).
b The overall mean expenditures were $4474 per patient.
Figure 3. Potential annual savings for Medicare from reducing
physician-attributable variation is shown. By using parame-
ters from our multilevel models and simulated datasets, we
changed all providers’ practice styles to be similar to those
of the physicians in 1 of the 20 treatment-intensity quantiles
(beginning at the 5th percentile and ending with the 95th
percentile). The figure illustrates the annual savings of these
changes for Medicare.
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DISCUSSION
A difference greater than 2-fold exists in expenditures for
early stage bladder cancer care delivered between the high-
est and lowest intensity providers. Approximately 9% of
this variation is attributable to physician factors. The size
of this physician effect exceeded that attributable to all
measurable patient characteristics and tumor stage and
grade. We observed no measurable benefit associated with
more intensive treatment for patients in terms of cancer-
specific survival or in the avoidance of a major interven-
tion. In fact, patients who received more intensive treat-
ment were more likely to undergo subsequent radical
cystectomy. If we reduced this potentially unwarranted
variation and aligned clinical practice with that of physi-
cians in the 25th percentile of treatment intensity, then
per capita Medicare expenditures could be lowered by
19% in the first 2 years after diagnosis. Such a reduction
would translate into an estimated annual cost savings of
nearly $19 million to theMedicare program.
Although, on the surface, the provider contribution
(9%) to treatment intensity variation that we observed
may seem small, it is meaningful and, compared with
other findings, relatively large. To provide some context,
the size of this physician effect is 4 times greater than the
corresponding effect for resource use at teaching hospi-
tals,25 3 times greater than that for prescribing rates
among general practitioners,26 and 2 times greater than
that in outpatient visits for diabetes care.27 Sources of
these between-provider differences in bladder cancer
treatment intensity probably are multiple. We attempted
to account for several physician factors (eg, provider case
volume and year of medical school graduation) that
demonstrably influence use9; however, their inclusion
explained little of the physician effect.
One explanation for this persistent physician-attrib-
utable variation pertains to the lack of empiricism under-
lying current guidelines. In contrast to other chronic
diseases like diabetes for which evidenced-based quality
indicators exist to direct care,28 consensus recommenda-
tions for early stage bladder cancer largely are limited to
expert opinion or nonexperimental data, leaving providers
with considerable ‘‘wiggle room’’ and, thereby, facilitating
practice style variation. Alternatively, external forces that
are not appreciable in the data may be fostering the
observed variation. For example, the threat of medical
liability may lead physicians to adopt assurance behavior,
whereby they supply additional services of marginal or no
medical value with the aim of deterring patients from fil-
ing malpractice claims.29
Our results must be viewed with several caveats.
First, although we observed substantial physician-attribut-
able variation, the majority of the variability in treatment
intensity still resided at the patient level, and we were able
to account for only 23% of these between-patient differ-
ences. Several yet unknown factors seem to influence the
observed variability in treatment intensity. Although it is
likely that patient preference and/or noncompliance con-
tributes to some of this variability, other possible factors
need to be explored. These factors may include the avail-
able supply of healthcare services (eg, the per capita num-
ber of urologists and medical oncologists for a given area
or the number of endoscopy suites within a market) and
local idiosyncrasies (ie, practices unique to a community
or small group of physicians that a provider adopts).
Second, unmeasured patient differences between
our physician quantiles might explain some of the practice
variation that we observed. We addressed this limitation
of observational data30,31 using a well developed approach
for measuring comorbidity19 and clinical registry data
linked with medical claims to ascertain cancer stage and
grade and recurrent disease status—arguably the most im-
portant determinants of patient outcomes in the bladder
cancer population.32,33 Third, the SEER-Medicare linked
data may not be generalizable to patients aged <65 years;
however, nearly 75% of bladder cancer diagnoses occur
among Medicare-aged patients.34 So, our findings are rel-
evant to the majority of the bladder cancer population.
Finally, we chose to focus on the treatment intensity that a
patient receives within the first 2 years of diagnosis. With
more than 500,000 bladder cancer survivors in the United
States (the majority of whom were diagnosed with early
stage disease and still require some form of surveillance35),
we probably are underestimating the magnitude of the
physician effect on expenditures. Therefore, the decreases
in total payments that we project after reducing physi-
cian-attributable variation are interpreted best as a floor,
and the savings to the Medicare program are potentially
much greater.
Having identified the provider level as a possible tar-
get, an examination of interventions to decrease practice
variation in early stage bladder cancer care is warranted.
Investigators have tried numerous strategies to alter physi-
cian behavior with variable succes.36 The literature on co-
lon polyp surveillance, an area in which considerable
between-provider differences also exist,37 illustrates the
utility of a continuous quality-improvement
approach.38,39 These initiatives aim to be inclusive and
involve all stakeholders in the process of system change
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rather than identifying and punishing outliers.40 With a
focus on provider retraining, continuous quality-improve-
ment programs can increase the uniformity of physician
care while reducing costs.38,39
In conclusion, althoughmuch of the variation in ini-
tial treatment intensity is determined by patient-level fac-
tors, relatively little is accounted for by those factors that
we commonly measure (eg, patient age, comorbid status,
tumor grade and stage, and subsequent disease recur-
rence). Furthermore, physician practice style appears to
contribute substantially to differences in treatment inten-
sity absent a demonstrable benefit to the patient. With up
to 33% of Medicare spending potentially wasted on
unnecessary (or even harmful) care,41 an intervention
aimed at reducing between-provider differences in treat-
ment intensity may improve the value of cancer care.
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